AUBAGIO® is a once-daily pill used to treat relapsing remitting multiple sclerosis (MS) that has been shown to quiet MS. AUBAGIO® (teriflunomide) is demonstrated consistent reduction in relapse rate, confirmed disability worsening, and multiple measures of MRI disease activity.
AUBAGIO is 14 mg tablet, can be taken any time of day, any place, with or without food. Your healthcare provider will decide which one is right for you.
Reference: Aubagio Hong Kong Prescribing Information.
LEMTRADA® is a CD52-directed humanized monoclonal antibody indicated for the treatment of patients with relapsing remitting multiple sclerosis with active disease defined by clinical or imaging features. LEMTRADA® is administered by intravenous infusion in 2 treatment courses. The first course will be given for 5 days in a row. Then one year later, the second course will be given for 3 days in a row. LEMTRADA® was proven to have superior efficacy vs IFN β-1a SC at 2 years. LEMTRADA® provides durable freedom for MS patients from disease activity confirmed without continued therapy.
Reference: Lemtrada Hong Kong Prescribing Information.